TWI821541B - Pth類似物之口服製劑及治療 - Google Patents

Pth類似物之口服製劑及治療 Download PDF

Info

Publication number
TWI821541B
TWI821541B TW109107457A TW109107457A TWI821541B TW I821541 B TWI821541 B TW I821541B TW 109107457 A TW109107457 A TW 109107457A TW 109107457 A TW109107457 A TW 109107457A TW I821541 B TWI821541 B TW I821541B
Authority
TW
Taiwan
Prior art keywords
pharmaceutical composition
oral pharmaceutical
containing compound
metal
group
Prior art date
Application number
TW109107457A
Other languages
English (en)
Chinese (zh)
Other versions
TW202100182A (zh
Inventor
史格瑞 葛林瑟
布尚 德魯庫碼 廸賽
Original Assignee
奧孟亞股份有限公司
史格瑞 葛林瑟
布尚 德魯庫碼 廸賽
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 奧孟亞股份有限公司, 史格瑞 葛林瑟, 布尚 德魯庫碼 廸賽 filed Critical 奧孟亞股份有限公司
Publication of TW202100182A publication Critical patent/TW202100182A/zh
Application granted granted Critical
Publication of TWI821541B publication Critical patent/TWI821541B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/32—Manganese; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/635—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW109107457A 2019-03-08 2020-03-06 Pth類似物之口服製劑及治療 TWI821541B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201921009082 2019-03-08
IN201921009082 2019-03-08

Publications (2)

Publication Number Publication Date
TW202100182A TW202100182A (zh) 2021-01-01
TWI821541B true TWI821541B (zh) 2023-11-11

Family

ID=72426161

Family Applications (1)

Application Number Title Priority Date Filing Date
TW109107457A TWI821541B (zh) 2019-03-08 2020-03-06 Pth類似物之口服製劑及治療

Country Status (6)

Country Link
US (1) US20220133857A1 (cg-RX-API-DMAC7.html)
JP (2) JP7610410B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210137373A (cg-RX-API-DMAC7.html)
CN (1) CN111971027A (cg-RX-API-DMAC7.html)
TW (1) TWI821541B (cg-RX-API-DMAC7.html)
WO (1) WO2020183318A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020183318A1 (en) * 2019-03-08 2020-09-17 Anya Biopharm Inc. Oral formulation and treatment of pth analog.
EP4226918A1 (en) * 2022-02-15 2023-08-16 Filip Majewski Pharmaceutical single dosage form for oral delivery of peptides
KR102844771B1 (ko) * 2022-07-22 2025-08-12 주식회사 아이큐어비앤피 테리파라타이드를 포함하는 골다공증 예방 또는 치료를 위한 경구용 약학적 조성물 및 이의 제조방법
WO2025037993A1 (en) 2023-08-13 2025-02-20 Filip Majewski Dosage form for peptide agents

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108135962A (zh) * 2015-10-07 2018-06-08 塞浦路迈德有限责任公司 用于口服递送肽类药物的药物制剂

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1228708A (zh) * 1996-09-04 1999-09-15 有限会社多特 经口给药用含肽药物组合物
US6946151B2 (en) * 2002-11-12 2005-09-20 Ayurvedic-Life International, Llc Therapeutic compositions
US20040121025A1 (en) * 2002-12-20 2004-06-24 Mckee Dwight Oral composition for the treatment and prevention of bone loss
JP2007525472A (ja) * 2003-07-04 2007-09-06 ニコメド ダンマーク エイピーエス 経口使用のための副甲状腺ホルモン(pth)含有医薬組成物
US9387235B2 (en) * 2004-06-14 2016-07-12 Basf Beauty Care Solutions France S.A.S. Cosmetic preparations containing PTH fragments
CN102123697B (zh) * 2008-08-18 2015-06-10 安特拉贝欧有限公司 用于口服给予蛋白质的方法和组合物
EP3016674A4 (en) * 2013-06-23 2017-03-15 Wisconsin Alumni Research Foundation Alpha-/beta-polypeptide analogs of parathyroid hormone (pth) and method of using same
DK3006045T3 (en) * 2014-10-07 2017-07-17 Cyprumed Gmbh Pharmaceutical formulations for oral administration of peptide or protein drugs
WO2016128972A1 (en) * 2015-02-09 2016-08-18 Entera Bio Ltd. Formulations for oral administration of active agents with controlled absorption profile
TWI751379B (zh) * 2017-09-21 2022-01-01 奧孟亞股份有限公司 用於遞送胜肽之藥物組合物
WO2020183318A1 (en) * 2019-03-08 2020-09-17 Anya Biopharm Inc. Oral formulation and treatment of pth analog.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108135962A (zh) * 2015-10-07 2018-06-08 塞浦路迈德有限责任公司 用于口服递送肽类药物的药物制剂

Also Published As

Publication number Publication date
KR20210137373A (ko) 2021-11-17
WO2020183318A1 (en) 2020-09-17
US20220133857A1 (en) 2022-05-05
JP2024178360A (ja) 2024-12-24
JP7610410B2 (ja) 2025-01-08
CN111971027A (zh) 2020-11-20
JP2022522550A (ja) 2022-04-20
TW202100182A (zh) 2021-01-01

Similar Documents

Publication Publication Date Title
KR100498646B1 (ko) 경구용 펩티드 약학적 조성물
JP2024178360A (ja) 副甲状腺ホルモンアナログの経口製剤および治療
CN101801309B (zh) 口服递送的肽药物
US10525018B2 (en) Calcifediol soft capsules
JP2010184945A (ja) 経口ペプチド医薬投与形および製造方法
JP2018529749A5 (cg-RX-API-DMAC7.html)
ES2929218T3 (es) Formas farmacéuticas orales sólidas
US20240041983A1 (en) Improved pharmaceutical formulations of glp-1 receptor agonists
KR20170061140A (ko) 펩티드 또는 단백질 약물의 경구 전달을 위한 약제학적 제형
EP2846780B1 (en) Solubilized capsule formulation of 1,1-dimethylethyl [(1s)-1-{[(2s,4r)-4-(7-chloro-4methoxyisoquinolin-1-yloxy)-2-({(1r,2s)-1-[(cyclopropylsulfonyl)carbamoyl]-2-ethenylcyclopropyl}carbamoyl)pyrrolidin-1-yl]carbonyl}-2,2-dimethylpropyl]carbamate
US20220313773A1 (en) Terlipressin compositions and their methods of use
JP2022132375A (ja) ペプチド送達のための医薬組成物
AU2017202900B2 (en) Pharmaceuticals for oral delivery
CN1809377B (zh) 包含微粉化形式的传送剂的口服给药药物组合物
US20220202907A1 (en) Formulations of Terlipressin
JP5892940B2 (ja) クラウン化合物及び/又は対イオンと複合体化されたペプチドを含む粘膜送達組成物
AU2005262576B2 (en) Oral delivery of peptide pharmaceutical compositions
EP4026566A1 (en) Oral pharmaceutical composition comprising teriparatide and method for preparing same
US12409139B2 (en) Stable parenteral formulations of duloxetine
US20260077020A1 (en) Oral peptide pharmaceutical composition that facilitates enhanced oral absorption
JP7300793B2 (ja) 室温で安定な経口カルシトニン製剤